Download video

The Potential of Technology Transfer | David Allen | TEDxTucsonSalon

53 views

TEDx Talks

3 weeks ago

The Potential of Technology Transfer | David Allen | TEDxTucsonSalon

The Potential of Technology Transfer | David Allen | TEDxTucsonSalon

Quantum Computing for Photon-Drug Interactions in Cancer Treatment | AIDAQ 2025
17:13
Quantum Computing for Photon-Drug Interactions in Cancer Treatment | AIDAQ 2025
by Bitkom Events
Integrating AI with other novel technologies to detect and prevent oesophageal cancer
2:38
Integrating AI with other novel technologies to detect and prevent oesophageal cancer
by PHGFoundation
Just 0.2 % of Chemotherapy Drugs Reach the Tumor. AI + Nanotech Could Change That.
49:24
Just 0.2 % of Chemotherapy Drugs Reach the Tumor. AI + Nanotech Could Change That.
by Lars Rinnan
AI supercharged quantum : what just changed recently in 2025
2:46
AI supercharged quantum : what just changed recently in 2025
by Tech-know
Prior2Former (ICCV 2025)
4:28
Prior2Former (ICCV 2025)
by TUM-DAML
Nikon Ti2 Polarized Micromanipulator: future in embryology
2:42
Nikon Ti2 Polarized Micromanipulator: future in embryology
by From Cells to Souls
TU2218, a TGFβ-RI and VEGFR2 dual inhibitor, with pembrolizumab in solid tumors
1:10
TU2218, a TGFβ-RI and VEGFR2 dual inhibitor, with pembrolizumab in solid tumors
by VJOncology
Keynote Presentation: Engineering Metabolically Fit, Memory-Rich CAR T cells for Treatment of Cancer
48:33
Keynote Presentation: Engineering Metabolically Fit, Memory-Rich CAR T cells for Treatment of Cancer
by Labroots
ADF2E75B65973D67C17E8C642A7C92#2
0:25
ADF2E75B65973D67C17E8C642A7C92#2
by River Valley Technologies
The Next Frontier in Cancer \& Longevity: NK Cell Exosomes | Dr. Jeff Gross | ANEW Ep 102
27:07
The Next Frontier in Cancer \& Longevity: NK Cell Exosomes | Dr. Jeff Gross | ANEW Ep 102
by ANEW Insight
ASCO 2023 Highlights on erdafitinib in metastatic urothelial cancer with select FGFR alterations
4:47
ASCO 2023 Highlights on erdafitinib in metastatic urothelial cancer with select FGFR alterations
by European Society for Medical Oncology (ESMO)
How to Treat Metastatic Non-Small Cell Lung Cancer w\/o Targeted Mut in Front-line - Dr. Preeshagul
25:28
How to Treat Metastatic Non-Small Cell Lung Cancer w\/o Targeted Mut in Front-line - Dr. Preeshagul
by OncBrothers: Practice-Changing Cancer Discussions
Local Therapies: New Technologies in Interventional Radiology
7:27
Local Therapies: New Technologies in Interventional Radiology
by KidneyCAN
943259795ACDEF619D3C8038A4382E#2
0:25
943259795ACDEF619D3C8038A4382E#2
by River Valley Technologies
Webinar: Dual-Function Multi-Engager Antibody for Simultaneous Targeting NK Cells and Tumor Cells
59:08
Webinar: Dual-Function Multi-Engager Antibody for Simultaneous Targeting NK Cells and Tumor Cells
by Creative Biolabs
Phase 2 NOBLE Study
3:27
Phase 2 NOBLE Study
by CheckRare
Phase II study of petosemtamab and pembrolizumab for recurrent\/metastatic HNSCC
3:15
Phase II study of petosemtamab and pembrolizumab for recurrent\/metastatic HNSCC
by VJOncology
The Evolution of HER2 Low in Metastatic Breast Cancer Therapy
1:07
The Evolution of HER2 Low in Metastatic Breast Cancer Therapy
by Innovative Oncology News
Initium Webinar 2
39:10
Initium Webinar 2
by The Viscosity Channel
2024PawseyInternANg
4:27
2024PawseyInternANg
by Pawsey Supercomputing Research Centre
January 2025 Turing-Roche Knowledge Share Event: Dynamic Precision Medicine
1:05:12
January 2025 Turing-Roche Knowledge Share Event: Dynamic Precision Medicine
by The Turing-Roche Strategic Partnership
A4168CA287E361E22E55CDB7E2B1D4#2
0:34
A4168CA287E361E22E55CDB7E2B1D4#2
by River Valley Technologies
UNITE Study: Sequencing Erdafitinib and EV for Patients With FGFR2\/3-Altered Disease
5:37
UNITE Study: Sequencing Erdafitinib and EV for Patients With FGFR2\/3-Altered Disease
by GU Oncology Now